SHAREHOLDER ALERT: HBNC FULC CRL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE /May 29, 2023 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Horizon Bancorp, Inc. (NASDAQ:HBNC)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/horizon-class-action-submission-form?prid=39990&wire=1
Lead Plaintiff Deadline: June 20, 2023
Class Period: March 9, 2022 - March 10, 2023

Allegations against HBNC include that: (i) the Company maintained deficient internal accounting controls relating to its classification of certain loan balances and securities; (ii) as a result of the foregoing deficiencies, throughout 2022 the Company issued quarterly financial statements containing errors that would require subsequent revision; (iii) restatement of the foregoing financial statements would hinder the Company's ability to timely file its annual report for 2022; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/fulcrum-class-action-submission-form?prid=39990&wire=1
Lead Plaintiff Deadline: June 27, 2023
Class Period: March 3, 2022 - March 8, 2023

Allegations against FULC include that: (i) the preclinical data submitted in support of FTX-6058 (an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies) showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Charles River Laboratories International, Inc. (NYSE:CRL)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/charles-river-class-action-submission-form?prid=39990&wire=1
Lead Plaintiff Deadline: July 18, 2023
Class Period: May 5, 2020 - February 21, 2023

Allegations against CRL include that: (1) Charles River had engaged in illegal activity with respect to its importation of non-human primates for research; (2) as a result, Charles River was at a heightened risk of criminal and regulatory investigation by, inter alia, the U.S. Department of Justice; (3) as a result, Charles River would be forced to suspend shipments of primates from Cambodia; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong